section name header

Pronunciation

pal-i-VI-zoo-mab

Classifications

Therapeutic Classification: antivirals

Pharmacologic Classification: monoclonal antibodies

Indications

REMS


Action

  • Neutralizes and inhibits fusion of RSV virus; subsequently inhibits viral replication.
Therapeutic effects:
  • Prevents serious sequelae of RSV disease in susceptible children.

Pharmacokinetics

Absorption: Well absorbed after IM administration.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: 20 days.

Time/Action Profile

(antibody levels)

ROUTEONSETPEAKDURATION
IMrapid48 hr30 days





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: rash

Hemat: thrombocytopenia

Local: erythema, induration

Neuro: fever

Misc: ANAPHYLACTOID REACTIONS AND ANAPHYLAXISHYPERSENSITIVITY REACTIONS INCLUDING

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Synagis